Skip to content
Screener

Pre-Tax Income at other companies

Arvinas logo
ArvinasARVN
-$57.5M-169%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$43.19M-289%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$8.3M+61.4%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$50M-144%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$74.03M-34.0%
CYP
Cypherpunk TechnologiesCYPH
-$82.28M-433%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemThree Months Ended May 31, 2026Three Months Ended May 31, 2025Six Months Ended May 31, 2026Six Months Ended May 31, 2025
Total operating expenses103,24792,378201,994173,695
Loss from operations(94,204)(48,322)(186,699)(111,186)
Interest and other income, net4,3985,6189,71912,131
Loss before income taxes(89,806)(42,704)(176,980)(99,055)
Provision for (benefit from) income taxes(271)760(271)760
Net loss$(89,535)$(43,464)$(176,709)$(99,815)
Net loss per share, basic and diluted$(0.81)$(0.52)$(1.60)$(1.19)
Weighted-average number of shares outstanding, basic and diluted111,084,42383,882,477110,583,61083,723,403

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s pre-tax income?
Nurix Therapeutics, Inc. (NRIX) reported pre-tax income of -$89.81M in Q1 2026.
How has Nurix Therapeutics, Inc.'s pre-tax income changed year-over-year?
Nurix Therapeutics, Inc.'s pre-tax income decreased by 110.3% year-over-year, from -$42.7M to -$89.81M.
What is the long-term trend for Nurix Therapeutics, Inc.'s pre-tax income?
Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s pre-tax income has grown at a 22.5% compound annual growth rate (CAGR), from -$117.06M to -$263.7M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Nurix Therapeutics, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude